Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KDR Q472H |
| Therapy | Dabrafenib + Lenvatinib + Trametinib |
| Indication/Tumor Type | melanoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KDR Q472H | melanoma | sensitive | Dabrafenib + Lenvatinib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Lenvima (lenvatinib) treatment to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) decreased proliferation compared to the combination alone in melanoma cell lines expressing KDR Q472H in culture (PMID: 38201446). | 38201446 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38201446) | Kinase Insert Domain Receptor Q472H Pathogenic Germline Variant Impacts Melanoma Tumor Growth and Patient Treatment Outcomes. | Full reference... |